Maine Elmiron Lawsuit Lawyers

Berman & Simmons Is Pursuing Claims Relating to Degenerative Eye Issues Caused by Elmiron

Berman & Simmons, Maine’s premier dangerous drug law firm, is currently investigating and pursuing claims on behalf of individuals in Maine and throughout New England who experienced significant vision problems after taking Elmiron. Compensation may be available in Elmiron vision loss litigation against the drug manufacturer. Our attorneys can meet with you for a free consultation to discuss your condition and your claims and determine whether you may be eligible to pursue damages for your injuries.

Elmiron and Ocular Damage

First approved by the U.S. Food and Drug Administration (FDA) in 1985, Elmiron is prescribed to treat interstitial cystitis, a chronic condition that causes severe bladder and pelvic pain. An estimated one million Americans, disproportionately women, live with the condition.
Studies beginning in 2018 showed a correlation between vision problems and long-term Elmiron use. Specifically, they found that Elmiron may cause pigmentary retinal maculopathy, a degenerative eye disorder that can lead to vision loss or blindness. Researchers found that up to 25 percent of Elmiron users showed signs of ocular toxicity and eye damage.
Besides vision loss, eye problems associated with pigmentary retinal maculopathy caused by Elmiron may include:

• Blurry vision.
• Night blindness.
• Difficulty reading.
• Dark spots.
• Loss of close vision.
• Visual dimming.

Failure to Warn of Known Risks Related to Elmiron

Even though there are known risks of vision loss and eye damage associated with Elmiron, the product remains on the market. Until June 2020, the drug’s manufacturer, Janssen Pharmaceuticals, a division of Johnson & Johnson put no warning on the product advising patients of the risk of macular damage, visual changes, or other eye conditions associated with Elmiron.
Elmiron’s label now warns that the medication can change pigments in the retina and cause blurred vision, reading problems, and sensitivity to low light. The new warning also notes that users’ eyesight may continue to deteriorate even after they stop using the drug.